Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.3300 (3.7%) ($5.1300 - $5.4000) on Mon. Feb. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.68% (three month average) | RSI | 48 | Latest Price | $5.3300(3.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TBT(13%) UUP(9%) KWEB(7%) IBB(6%) SMH(6%) | Factors Impacting ADMS price | ADMS will decline at least -3.84% in a week (0% probabilities). PCY(-21%) BWX(-21%) BNDX(-19%) EMHY(-17%) BND(-17%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.84% (StdDev 7.68%) | Hourly BBV | 0 () | Intraday Trend | 1.7% | | | |
|
Resistance Level | $5.38 | 5 Day Moving Average | $5.23(1.91%) | 10 Day Moving Average | $5.46(-2.38%) | 20 Day Moving Average | $5.38(-0.93%) | To recent high | -27% | To recent low | 4.5% | Market Cap | $151m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |